Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...
Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Bloomberg on MSN6d
Alzheimer’s drugs eyed as next big obesity-like opportunityInvestors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback